Inivata Collaborates with Genomics England to Assess Samples and Explore Potential of Liquid Biopsy to Improve Cancer Management and Patient Outcomes
Pilot study to test Genomics England samples using Inivata’s InVisionTM platform
Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces that it is collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and patient outcomes.
In the first phase of a larger pilot, Inivata will analyse plasma samples donated by participants in Genomics England’s 100,000 Genomes Project. As well as determining the suitability of plasma, the study will focus on the use of Inivata’s world-leading liquid biopsy technology, InVision, to discover the mutations in the human genome that can lead to or demonstrate the presence of cancer.
These results, and those from the two subsequent phases, will be shared with researchers in the UK and around the world − with the potential to develop less invasive sample collection techniques, more effective monitoring processes and, ultimately, better cancer care.
Michael Stocum, Chief Executive Officer of Inivata, said:
“As a company with a strong UK heritage, we are delighted to have partnered with the 100,000 Genomes Project – a world-leading initiative which is committed to keeping the UK at the forefront of medical innovation and care. This pilot study will enable us to combine our efforts through the sharing of insights and the assessment of how liquid biopsy technology could ultimately transform cancer care within the NHS, saving lives and money.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.